Start here: prostate cancer, from screening to recurrence
from FRCS in 15
The best place to begin: the highest-yield topic in the exam, at the pace the rest of the series runs. What the screening trials really show and why they only look contradictory, the MRI-first pathway and biparametric scanning, why the biopsy left the operating theatre, the T2 change people miss, who actually needs staging imaging, why three surgery-versus-monitoring trials disagree, when a benign biopsy is not reassuring, and the two recurrence definitions you must not mix up.
Embed this episode
No transcript yet.
Similar podcasts
Frequently asked questions
How long is this episode of FRCS in 15?
This episode is 18 minutes long.
When was this FRCS in 15 episode published?
This episode was published on September 20, 2026.
Can I download this FRCS in 15 episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.